194 related articles for article (PubMed ID: 20465314)
1. Methodological concerns with economic evaluations of meningococcal vaccines.
Kauf TL
Pharmacoeconomics; 2010; 28(6):449-61. PubMed ID: 20465314
[TBL] [Abstract][Full Text] [Related]
2. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
3. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
5. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
Christensen H; Trotter CL; Hickman M; Edmunds WJ
BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of meningococcal vaccines: considerations for the future.
Christensen H; Al-Janabi H; Levy P; Postma MJ; Bloom DE; Landa P; Damm O; Salisbury DM; Diez-Domingo J; Towse AK; Lorgelly PK; Shah KK; Hernandez-Villafuerte K; Smith V; Glennie L; Wright C; York L; Farkouh R
Eur J Health Econ; 2020 Mar; 21(2):297-309. PubMed ID: 31754924
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.
Arifin SMN; Zimmer C; Trotter C; Colombini A; Sidikou F; LaForce FM; Cohen T; Yaesoubi R
Med Decis Making; 2019 Jul; 39(5):553-567. PubMed ID: 31268405
[No Abstract] [Full Text] [Related]
10. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
[TBL] [Abstract][Full Text] [Related]
12. Potential long term vaccine benefits poorly translate in cost effectiveness modelling.
Black S
BMJ; 2014 Nov; 349():g6764. PubMed ID: 25394571
[No Abstract] [Full Text] [Related]
13. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.
Miller MA; Shahab CK
Pharmacoeconomics; 2005; 23(4):333-43. PubMed ID: 15853434
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.
Cortés I; Pérez-Camarero S; Del Llano J; Peña LM; Hidalgo-Vega A
Vaccine; 2013 Aug; 31(35):3473-84. PubMed ID: 23764534
[TBL] [Abstract][Full Text] [Related]
15. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.
Nymark LS; Sharma T; Miller A; Enemark U; Griffiths UK
Vaccine; 2017 Dec; 35(49 Pt B):6828-6841. PubMed ID: 29146380
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.
Anonychuk AM; Tricco AC; Bauch CT; Pham B; Gilca V; Duval B; John-Baptiste A; Woo G; Krahn M
Pharmacoeconomics; 2008; 26(1):17-32. PubMed ID: 18088156
[TBL] [Abstract][Full Text] [Related]
17. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.
Gibson E; Begum N; Sigmundsson B; Sackeyfio A; Hackett J; Rajaram S
Hum Vaccin Immunother; 2016 May; 12(5):1202-16. PubMed ID: 26837602
[TBL] [Abstract][Full Text] [Related]
19. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
20. Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
Jit M; Hutubessy R
Appl Health Econ Health Policy; 2016 Jun; 14(3):245-52. PubMed ID: 26832145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
